Supplemental material for JAAD publication titled: A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results"
Published: 10 September 2021| Version 5 | DOI: 10.17632/vn3spwfg52.5
Contributor:
Nina MagnoloDescription
Supplemental material for JAAD publication titled: "A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results" to be published in Journal of the American Academy of Dermatology
Files
Categories
Dermatology, Pediatrics, Psoriasis